HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Methylenetetrahydrofolate reductase C677T polymorphism predicts response and time to progression to gemcitabine-based chemotherapy for advanced non-small cell lung cancer in a Chinese Han population.

AbstractOBJECTIVE:
The aim of this study was to evaluate the association between the methylenetetrahydrofolate reductase (MTHFR) C677T excision repair cross-complementation group 1 (ERCC1) genetic polymorphisms and the clinical efficacy of gemcitabine-based chemotherapy in advanced non-small cell lung cancer (NSCLC).
METHODS:
A total of 135 chemonaive patients with unresectable advanced NSCLC were treated with gemcitabine/platinum regimens. The polymorphisms of MTHFR C677T, ERCC1 C8092A, and ERCC1 C118T were genotyped using the TaqMan methods.
RESULTS:
The overall response rate was 28.9%. Patients with MTHFR CC genotype had a higher rate of objective response than patients with variant genotype (TT or CT) (41.2% versus 19.1%, P=0.01). Median time to progression (TTP) of patients with MTHFR CC genotype was longer than that of patients with variant genotype (7.6 months versus 5.0 months, P=0.003). No significant associations were obtained between ERCC1 C118T and C8092A polymorphisms and both response and survival.
CONCLUSIONS:
Our data suggest the value of MTHFR C677T polymorphism as a possible predictive marker of response and TTP in advanced NSCLC patients treated with gemcitabine/platinum.
AuthorsWei Hong, Kai Wang, Yi-ping Zhang, Jun-yan Kou, Dan Hong, Dan Su, Wei-min Mao, Xin-min Yu, Fa-jun Xie, Xiao-jian Wang
JournalJournal of Zhejiang University. Science. B (J Zhejiang Univ Sci B) Vol. 14 Issue 3 Pg. 207-15 (Mar 2013) ISSN: 1862-1783 [Electronic] China
PMID23463763 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antimetabolites, Antineoplastic
  • Genetic Markers
  • Deoxycytidine
  • Methylenetetrahydrofolate Reductase (NADPH2)
  • Gemcitabine
Topics
  • Adult
  • Aged
  • Antimetabolites, Antineoplastic (therapeutic use)
  • Carcinoma, Non-Small-Cell Lung (drug therapy, epidemiology, genetics)
  • China (epidemiology)
  • Deoxycytidine (analogs & derivatives, therapeutic use)
  • Female
  • Genetic Markers (genetics)
  • Genetic Predisposition to Disease (epidemiology, genetics)
  • Humans
  • Lung Neoplasms (drug therapy, epidemiology, genetics)
  • Male
  • Methylenetetrahydrofolate Reductase (NADPH2) (genetics)
  • Middle Aged
  • Outcome Assessment, Health Care (methods, statistics & numerical data)
  • Polymorphism, Single Nucleotide (genetics)
  • Prevalence
  • Reproducibility of Results
  • Retrospective Studies
  • Sensitivity and Specificity
  • Treatment Outcome
  • Gemcitabine

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: